KAZIA THERAPEUTICS LTD
Company Information
Industry Pharmaceutical Preparations
SIC Code 2834
Entity Type operating
SEC Category Non-accelerated filer
State of Incorporation Australia
Country Australia
Business Address THREE INTERNATIONAL TOWERS LEVEL 24,, SYDNEY NSW, , 2000
Mailing Address THREE INTERNATIONAL TOWERS LEVEL 24,, SYDNEY NSW, , 2000
Phone 01161298780088
Fiscal Year End 0630
EIN 000000000
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| SCHEDULE 13G/A Passive ownership amendment | February 12, 2026 | View on SEC |
| 6-K Foreign company current report | January 27, 2026 | View on SEC |
| SCHEDULE 13G Passive beneficial ownership (>5%) | January 23, 2026 | View on SEC |
| F-1 Foreign company IPO registration | December 19, 2025 | View on SEC |
| 6-K Foreign company current report | December 19, 2025 | View on SEC |
| F-1/A Foreign IPO registration amendment | December 19, 2025 | View on SEC |
| 6-K Foreign company current report | December 10, 2025 | View on SEC |
| 6-K Foreign company current report | December 5, 2025 | View on SEC |
| 6-K Foreign company current report | December 2, 2025 | View on SEC |
| 6-K Foreign company current report | November 18, 2025 | View on SEC |
Annual Reports
20-F November 7, 2025
- FDA granted paxalisib 'Fast Track' status to expedite reviews.
- Partnered with St. Jude’s Hospital to share trial costs.
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.